Hospital sales outreach has begun ahead of January deliveries as NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) said on Wednesday it activated a 17-person team for U.S.-made preservative-free ketamine. NRx expects gross and net sales margins above 50 per cent, although the launch release discloses no product price or purchase quantities. The Nov. 11 announcement targets initial supply agreements and preorders in late 2026, followed by shipments in Jan…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.